Almonertinib
- Generic Name
- Almonertinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H35N7O2
- CAS Number
- 1899921-05-1
- Unique Ingredient Identifier
- T4RS462G19
- Background
Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
- Indication
1.用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M 突变阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。
2.用于表皮生长因子受体（EGFR）敏感突变阳性局部晚期或转移性非小细胞肺癌（NSCLC）患者一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 606
- Registration Number
- NCT04762459
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center, Shenzhen, China
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
- Conditions
- Interventions
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 192
- Registration Number
- NCT04687241
- Locations
- 🇨🇳
Jilin Province Cancer Hospital, Changchun, Jilin, China
A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- First People's Hospital of Hangzhou
- Target Recruit Count
- 47
- Registration Number
- NCT04643847
- Locations
- 🇨🇳
Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- First People's Hospital of Hangzhou
- Target Recruit Count
- 43
- Registration Number
- NCT04636593
- Locations
- 🇨🇳
Hangzhou Cancer hospital, Hangzhou, Zhejiang, China
Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 226
- Registration Number
- NCT04592666
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2020-10-14
- Target Recruit Count
- 53
- Registration Number
- NCT04553887
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation
- Conditions
- Interventions
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2020-08-05
- Target Recruit Count
- 460
- Registration Number
- NCT04500717
- Locations
- 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Peking University International Hospital, Beijing, China
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2020-08-05
- Target Recruit Count
- 166
- Registration Number
- NCT04500704
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2020-07-02
- Target Recruit Count
- 168
- Registration Number
- NCT04455594
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT04354961
- Locations
- 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.